Jeffrey Cummings discusses Drug Development & the Changing Alzheimer's Disease Therapeutic Landscape

Dr. Jeffrey Cummings discusses the changing Alzheimer's Disease Therapeutic Landscape. Key learnings include:
-Candidate treatments in the drug development pipeline are directed at a wide variety of targets
-Biomarkers play multiple key roles in Alzheimer’s drug development
-Anti-amyloid monoclonal antibodies are making progress toward approval and possible clinical implementation
#alzheimersawareness #alzheimersdisease #drugdevelopment #clinicaltrials